Cornerstone Pharmaceuticals

A Singular Focus on Cancer Metabolism

  • About
    • Overview
    • Leadership
    • Non-Executive Directors
    • Advisory Board Members
  • Cancer Metabolism
    • Overview
    • Our Approach
  • Platforms & Pipelines
    • Pipeline
    • AEMD/CPI-613
    • Emulsiphan/EmPAC
  • Clinical Trials
  • News & Media
    • Press Releases
    • News Coverage
    • Press Kit
    • Press Contacts
    • Scientific Papers and Abstracts
  • Careers
  • Contact
Home > News & Media > Press Kit

Press Kit

Individual Press Info

  • Cornerstone Corporate Fact Sheet
  • Cancer Metabolism Backgrounder
  • Emulsiphan Fact Sheet
  • AEMD

Bios

  • Paul Bingham
  • King Lee
  • David Polinsky
  • Robert Rodriguez
  • Rob Shorr
  • Cliff Straub
  • Tim Sullivan
inner-4
  • News

December 12, 2011 Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia

More View All

Copyright 2012 © Cornerstone Pharmaceuticals, Inc. All Rights Reserved.Privacy Policy | Terms & Conditions

  • Home
  • About Us
    • Overview
    • Leadership
    • Non-Executive Directors
    • Advisory Board Members
  • Cancer Metabolism
    • Overview
    • Our Approach
  • Platforms & Pipelines
    • Pipeline
    • AEMD/CPI-613
    • Emulsiphan/EmPAC
  • Clinical Trials
  • News & Media
    • Press Releases
    • News Coverage
    • Press Kit
    • Press Contacts
    • Scientific Papers and Abstracts
  • Careers
  • Contact

Cornerstone Pharmaceuticals Using its profound and proprietary understanding of cancer metabolism,
Cornerstone is dedicated to revolutionizing the way cancer is treated.

Website Design by Jackrabbit Design

Follow us on Twitter